RePORT ⟩ RePORTER

Project Details

HHSN261201200021I/HHSN26100007Preclinical In Vitro and In Vivo Development Assays for Cancer Preventative Reagent. Project Title: Effect of Bazedoxifene Either Alone or in Combination with an Aroma

Project Number261201200021I-0-26100007-1

Contact PI/Project LeaderGRUBBS, CLINTON

Awardee OrganizationUNIVERSITY OF ALABAMA AT BIRMINGHAM

Description

Abstract Text

This contract is to assess the new third-generation SERM, Bazedoxifene, alone and in combination with CE and/or an AI, to prevent mammary carcinogenesis induced in virgin female Sprague-Dawley rats by N-methyl-N-nitrosourea (MNU). The tasks will involve optimizing the dose and timing of BZA administration, and PK profile of BZA in combination with the AI.

Public Health Relevance Statement

Data not available.

NIH Spending Category

Breast CancerCancerPrevention

Project Terms

AnimalsBiological MarkersChemopreventive AgentContractorContractsDataDoseExperimental ModelsFemaleGenerationsHistologicIn VitroLesionMalignant NeoplasmsMammary NeoplasmsMammary TumorigenesisMaximum Tolerated DoseMethodologyMethylnitrosoureaMolecular TargetNitrosourea CompoundsProtocols documentationReagentRouteSelective Estrogen Receptor ModulatorsSignal PathwaySignal TransductionSprague-Dawley RatsTestingTimeTissue Banksanimal age groupassay developmentdesignin vivopreventtumor

Details

Contact PI/ Project Leader

Name

GRUBBS, CLINTON

Title

Contact

Other PIs

Not Applicable

Program Official

Name

Contact

Email not available

Organization

Name

UNIVERSITY OF ALABAMA AT BIRMINGHAM

City

BIRMINGHAM

Country

UNITED STATES (US)

Department Type

Unavailable

Organization Type

Domestic Higher Education

State Code

Congressional District

Other Information

Opportunity Number

Study Section

Fiscal Year

2014

Award Notice Date

Administering Institutes or Centers

National Cancer Institute

CFDA Code

DUNS Number

063690705

UEI

YND4PLMC9AN7

Project Start Date

12-September-2014

Project End Date

11-September-2016

Budget Start Date

Budget End Date

Project Funding Information for 2014

Total Funding

$545,105

Direct Costs

Indirect Costs

Year	Funding IC	FY Total Cost by IC
2014	National Cancer Institute	$545,105

NIH Categorical SpendingClick here for more information on NIH Categorical Spending

Funding IC	FY Total Cost by IC	NIH Spending Category
NATIONAL CANCER INSTITUTE	$545,105	Breast Cancer; Cancer; Prevention

Sub Projects

No Sub Projects information available for 261201200021I-0-26100007-1

Publications

Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.

No Publications available for 261201200021I-0-26100007-1

Patents

No Patents information available for 261201200021I-0-26100007-1

Outcomes

The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.

No Outcomes available for 261201200021I-0-26100007-1

Clinical Studies

No Clinical Studies information available for 261201200021I-0-26100007-1

News and More

Section Menu